Members

Investor Relations Update June 5, 2025

We are pleased to provide the following updates on recent developments and financial matters.

Financial and Governance Updates:

On June 5, 2025, the MediXall Group Inc 10-Q for the second quarter of 2024 was filed with the U.S. Securities and Exchange Commission. You can access and review this 10-Q by going to the Investor Update under the Investor Relations tab at https://www.healthkarmagroup.com/ .

Below are 2 significant excerpts from this filing:

• Although revenue was down 26% from the same quarter in 2023, revenue for the six-month period grew 14% over the same six-month period in 2023. The drop in Q2revenue was due to a key client restructuring their program which caused a temporary pause in their offering from the end of April 2024 to September 2024.
• Moreover, the Company successfully reduced its net loss in the first six months of 2024by over $1.2 million from the same period in 2023. The net loss for the six months ended June 30, 2024 was $972,462 versus $2,200,873 for the same period in 2023.

Our team is working diligently with our auditors and anticipate the final 2024 10-Q report for the3rd Quarter will be filed shortly. We appreciate your patience and understanding as we prioritize accuracy and compliance in this process.

We remain focused on driving growth, fostering innovation, and delivering value to our stakeholders. Thank you for your continued support and confidence in our mission.

For further inquiries, please contact us via:
• Email: IR@healthkarmagroup.com
• Voice Message: (954) 737-3435
• Investor Relations Tab: https://www.healthkarmagroup.com/

Yours in health and progress,

Health Karma Investor Relations